OPNT Key Statistics, Chart & Performance
The current stock price of OPNT is 20.65 USD. In the past month the price increased by 2.33%. In the past year, price decreased by -22.31%.
OPNT Latest News, Press Relases and Analysis
OPNT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.94 | 955.13B | ||
| JNJ | JOHNSON & JOHNSON | 19.45 | 486.51B | ||
| MRK | MERCK & CO. INC. | 11.32 | 247.51B | ||
| PFE | PFIZER INC | 8.13 | 148.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.95 | 106.16B | ||
| ZTS | ZOETIS INC | 18.71 | 52.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 22.93B | ||
| VTRS | VIATRIS INC | 4.69 | 12.59B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.81 | 10.88B | ||
| CORT | CORCEPT THERAPEUTICS INC | 97.85 | 9.06B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.52B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.23B |
Related stock screener links
About OPNT
Company Profile
Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The company is headquartered in Santa Monica, California and currently employs 37 full-time employees. The company went IPO on 2017-09-18. The firm developed NARCAN (naloxone hydrochloride) Nasal Spray (NARCAN), a treatment to reverse opioid overdose. The firm's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), and Acute Cannabinoid Overdose (ACO). The firm is also pursuing other treatment opportunities within the addiction and drug overdose field. Its lead development product is OPNT003 a nasal nalmefene for the treatment of opioid overdose.
Company Info
OPIANT PHARMACEUTICALS INC
233 Wilshire Blvd, Suite 400
Santa Monica CALIFORNIA 90401 US
CEO: Roger Crystal
Employees: 37
Phone: 13105985410.0
OPIANT PHARMACEUTICALS INC / OPNT FAQ
What does OPNT do?
Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The company is headquartered in Santa Monica, California and currently employs 37 full-time employees. The company went IPO on 2017-09-18. The firm developed NARCAN (naloxone hydrochloride) Nasal Spray (NARCAN), a treatment to reverse opioid overdose. The firm's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), and Acute Cannabinoid Overdose (ACO). The firm is also pursuing other treatment opportunities within the addiction and drug overdose field. Its lead development product is OPNT003 a nasal nalmefene for the treatment of opioid overdose.
What is the current price of OPNT stock?
The current stock price of OPNT is 20.65 USD. The price decreased by -0.58% in the last trading session.
Does OPNT stock pay dividends?
OPNT does not pay a dividend.
What is the ChartMill technical and fundamental rating of OPNT stock?
OPNT has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for OPNT stock?
7 analysts have analysed OPNT and the average price target is 21.42 USD. This implies a price increase of 3.73% is expected in the next year compared to the current price of 20.65.
Can you provide the sector and industry classification for OPIANT PHARMACEUTICALS INC?
OPIANT PHARMACEUTICALS INC (OPNT) operates in the Health Care sector and the Pharmaceuticals industry.
What is the ownership structure of OPIANT PHARMACEUTICALS INC (OPNT)?
You can find the ownership structure of OPIANT PHARMACEUTICALS INC (OPNT) on the Ownership tab.
OPNT Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to OPNT. When comparing the yearly performance of all stocks, OPNT is a bad performer in the overall market: 63.88% of all stocks are doing better.
OPNT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to OPNT. The financial health of OPNT is average, but there are quite some concerns on its profitability.
OPNT Financial Highlights
Over the last trailing twelve months OPNT reported a non-GAAP Earnings per Share(EPS) of -6.55. The EPS decreased by -13200% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.6 |
OPNT Forecast & Estimates
7 analysts have analysed OPNT and the average price target is 21.42 USD. This implies a price increase of 3.73% is expected in the next year compared to the current price of 20.65.
For the next year, analysts expect an EPS growth of -2455.56% and a revenue growth -80.95% for OPNT